Browse CX3CR1

Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for the CX3C chemokine fractalkine (CX3CL1); binds to CX3CL1 and mediates both its adhesive and migratory functions (PubMed:9390561, PubMed:23125415). Acts as coreceptor with CD4 for HIV-1 virus envelope protein (in vitro) (PubMed:9726990). Isoform 2 and isoform 3 seem to be more potent HIV-1 coreceptors than isoform 1 (PubMed:14607932).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001774 microglial cell activation
GO:0002052 positive regulation of neuroblast proliferation
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002281 macrophage activation involved in immune response
GO:0002282 microglial cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002544 chronic inflammatory response
GO:0002545 chronic inflammatory response to non-antigenic stimulus
GO:0002676 regulation of chronic inflammatory response
GO:0002677 negative regulation of chronic inflammatory response
GO:0002880 regulation of chronic inflammatory response to non-antigenic stimulus
GO:0002881 negative regulation of chronic inflammatory response to non-antigenic stimulus
GO:0006968 cellular defense response
GO:0007405 neuroblast proliferation
GO:0007611 learning or memory
GO:0007613 memory
GO:0010720 positive regulation of cell development
GO:0016525 negative regulation of angiogenesis
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021795 cerebral cortex cell migration
GO:0021885 forebrain cell migration
GO:0021987 cerebral cortex development
GO:0022029 telencephalon cell migration
GO:0030336 negative regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0030900 forebrain development
GO:0031348 negative regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0038034 signal transduction in absence of ligand
GO:0040013 negative regulation of locomotion
GO:0042116 macrophage activation
GO:0044708 single-organism behavior
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0048167 regulation of synaptic plasticity
GO:0048246 macrophage chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050804 modulation of synaptic transmission
GO:0050806 positive regulation of synaptic transmission
GO:0050890 cognition
GO:0050900 leukocyte migration
GO:0051271 negative regulation of cellular component movement
GO:0051962 positive regulation of nervous system development
GO:0060291 long-term synaptic potentiation
GO:0060326 cell chemotaxis
GO:0061351 neural precursor cell proliferation
GO:0070098 chemokine-mediated signaling pathway
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0097529 myeloid leukocyte migration
GO:1900271 regulation of long-term synaptic potentiation
GO:1900272 negative regulation of long-term synaptic potentiation
GO:1901099 negative regulation of signal transduction in absence of ligand
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1902692 regulation of neuroblast proliferation
GO:1904018 positive regulation of vasculature development
GO:2000146 negative regulation of cell motility
GO:2000177 regulation of neural precursor cell proliferation
GO:2000179 positive regulation of neural precursor cell proliferation
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000648 positive regulation of stem cell proliferation
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function GO:0001637 G-protein coupled chemoattractant receptor activity
GO:0001653 peptide receptor activity
GO:0004896 cytokine receptor activity
GO:0004950 chemokine receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0016495 C-X3-C chemokine receptor activity
GO:0019955 cytokine binding
GO:0019956 chemokine binding
GO:0019960 C-X3-C chemokine binding
Cellular Component GO:0032809 neuronal cell body membrane
GO:0043025 neuronal cell body
GO:0044297 cell body
GO:0044298 cell body membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CX3CR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CX3CR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16525992Melanoma; Colon CarcinomaPromote immunity (infiltration)Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Fractalkine (CX3CL1) is a unique membrane-bound CX3C chemokine that serves as a potent chemoattractant for lymphocytes. Consistent with the finding, the intratumoral administration of Ad-FKN-transduced DC evoked tumor-specific cytotoxic T lymphocytes, which ensued from in vivo priming of Th1 immune responses in the treated host.
17372897B16 Malignant MelanomaPromote immunity (T/NK cell function)We found that B16-treated CX3CR1-/- mice had increased lung tumor burden and cachexia. However, CX3CR1-deficient NK cells exhibited a tumorigenic cytokine production profile with defective IFN-gamma expression and enhanced IL-6 production in response to TLR3 activation with polyIC. Our studies indicate that CX3CR1 is an important contributor to innate immunity at multiple levels.
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CX3CR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CX3CR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7180.159
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8640.328
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6090.418
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2610.672
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3010.776
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2120.86
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1180.783
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6050.458
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3610.666
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1120.431
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3420.524
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3020.0933
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CX3CR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CX3CR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CX3CR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CX3CR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CX3CR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CX3CR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CX3CR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCX3CR1
Namechemokine (C-X3-C motif) receptor 1
Aliases CMKDR1; V28; GPR13; CMKBRL1; chemokine (C-X3-C) receptor 1; GPRV28; C-X3-C CKR-1; CMK-BRL-1; CMK-BRL1; G pro ......
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CX3CR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.